The impact of prophylactic oral ganciclovir therapy on the incidence of cytomegalovirus (CMV) disease, patient and graft survival, and costs in patients receiving kidney and liver transplants is ...

Assuming the agency follows the advice of its experts, patients wrestling ... first approved treatment for adult transplant recipients with refractory CMV infection and disease, with or without ...

Whether this approach is applicable to other patients who may be at high risk of CMV disease, such as CMV-seropositive transplant recipients who receive antilymphocyte globulin induction therapy ...

In November 2017, just a few months after the previous Hutch symposium was held in Seattle, the U.S. Food and Drug Administration approved letermovir, a new antiviral targeting CMV infection in ...

CMV infection and CMV disease developed within 120 days after liver transplantation in 6 (5%) and 1 (0.8%), respectively, of 124 patients treated with intravenous ganciclovir (6 mg/kg/day ...

Livtencity (maribavir) has been cleared for use in transplant patients aged ... the activity of a CMV enzyme called pUL97 that is essential for replication of the virus, and also avoids some ...

Study reveals surprising connection between common childhood virus CMV and Alzheimer's disease, offering new insights into ...

The virus was traced in the bodies of three patients from Melbourne who died in the few weeks following the transplant of organs from a 57 year old brain dead patient. According to experts ...

The Cytomegalovirus (CMV) Infection market growth is driven by factors like increase in the prevalence of Cytomegalovirus ...

Professor Khanna said the analysis details the clinical improvement in 46 of the 71 patients who received ... such as Epstein–Barr virus (EBV), cytomegalovirus (CMV), BK polyomavirus, John ...